PURPOSE: To determine the ability of endorectal magnetic resonance imaging (erMRI) and other pretreatment factors to predict the presence and extent of extraprostatic extension (EPE) in men with Gleason score (GS) 7 prostate cancer. METHODS AND MATERIALS: We included patients with clinical stage T1c-T2c, GS=7 (3+4 or 4+3), and prostate-specific antigen (PSA) <10ng/mL who underwent pre-prostatectomy erMRI. We compared pathologic EPE findings with pretreatment factors. RESULTS: One hundred seventy-one men were eligible for inclusion. Pretreatment characteristics were: median age=60 years (42-76); median PSA 4.9ng/mL (0.4-9.9); GS 3+4=61%; T1c=51%; T2a=25%; T2b=21%; T2c=3%; ≥50% positive cores=46%; EPE-positive (EPE+) erMRI=28%. Thirty-three percent had pathologic EPE. Increasing T-stage (p<0.0001) and EPE+ erMRI (p<0.0001) were significant predictors of pathologic EPE, whereas GS (4+3 vs. 3+4) (p=0.14), percentage of positive core biopsies (p=0.15), and pretreatment PSA (p=0.41) were not. Median EPE distance was 1.75mm (range, <1-15mm). The rates of EPE >5mm and EPE >3mm were 11% and 15%, respectively. The odds ratios for erMRI detection of any EPE and of EPE >5mm were 3.06 and 3.75, respectively. CONCLUSIONS: T-stage and EPE+ erMRI predict pathologic EPE in men with GS 7 prostate cancer. The ability of erMRI to detect EPE increases with increasing EPE distance. These findings may be useful in patient selection for prostate brachytherapy monotherapy.
PURPOSE: To determine the ability of endorectal magnetic resonance imaging (erMRI) and other pretreatment factors to predict the presence and extent of extraprostatic extension (EPE) in men with Gleason score (GS) 7 prostate cancer. METHODS AND MATERIALS: We included patients with clinical stage T1c-T2c, GS=7 (3+4 or 4+3), and prostate-specific antigen (PSA) <10ng/mL who underwent pre-prostatectomy erMRI. We compared pathologic EPE findings with pretreatment factors. RESULTS: One hundred seventy-one men were eligible for inclusion. Pretreatment characteristics were: median age=60 years (42-76); median PSA 4.9ng/mL (0.4-9.9); GS 3+4=61%; T1c=51%; T2a=25%; T2b=21%; T2c=3%; ≥50% positive cores=46%; EPE-positive (EPE+) erMRI=28%. Thirty-three percent had pathologic EPE. Increasing T-stage (p<0.0001) and EPE+ erMRI (p<0.0001) were significant predictors of pathologic EPE, whereas GS (4+3 vs. 3+4) (p=0.14), percentage of positive core biopsies (p=0.15), and pretreatment PSA (p=0.41) were not. Median EPE distance was 1.75mm (range, <1-15mm). The rates of EPE >5mm and EPE >3mm were 11% and 15%, respectively. The odds ratios for erMRI detection of any EPE and of EPE >5mm were 3.06 and 3.75, respectively. CONCLUSIONS: T-stage and EPE+ erMRI predict pathologic EPE in men with GS 7 prostate cancer. The ability of erMRI to detect EPE increases with increasing EPE distance. These findings may be useful in patient selection for prostate brachytherapy monotherapy.
Authors: K Kenneth Chao; Neal S Goldstein; Di Yan; Carlos E Vargas; Michel I Ghilezan; Howard J Korman; Kenneth M Kernen; Jay B Hollander; Jose A Gonzalez; Alvaro A Martinez; Frank A Vicini; Larry L Kestin Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-05 Impact factor: 7.038
Authors: Steven J Frank; V Elayne Arterbery; I-Chow Joe Hsu; May Abdel-Wahab; Jay P Ciezki; Noah M Hahn; James Lloyd Mohler; Brian J Moran; Seth A Rosenthal; Carl J Rossi; Yoshiya Yamada; Gregory Merrick Journal: Brachytherapy Date: 2011-04-16 Impact factor: 2.362
Authors: Michael E Chen; Dennis Johnston; Adriana O Reyes; Cindy P Soto; R Joseph Babaian; Patricia Troncoso Journal: Am J Surg Pathol Date: 2003-10 Impact factor: 6.394
Authors: A V D'Amico; R Whittington; M Schnall; S B Malkowicz; J E Tomaszewski; D Schultz; A Wein Journal: Cancer Date: 1995-05-01 Impact factor: 6.860
Authors: David J Schwartz; Shomik Sengupta; David W Hillman; Daniel J Sargent; John C Cheville; Torrence M Wilson; Lance A Mynderse; Richard Choo; Brian J Davis Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-01 Impact factor: 7.038
Authors: Jennifer Salerno; Antonio Finelli; Chris Morash; Scott C Morgan; Nicholas Power; Nichola Schieda; Masoom A Haider Journal: Can Urol Assoc J Date: 2016-10-13 Impact factor: 1.862
Authors: Bradley J Stish; Brian J Davis; Lance A Mynderse; Robert H McLaren; Christopher L Deufel; Richard Choo Journal: Transl Androl Urol Date: 2018-06